Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A

References

• Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801–1809.
   PubMed Web of Science ®Google Scholar
• Auerswald G, Dolan G, Duffy A, et al. Pain and pain management in haemophilia. Blood Coagul Fibrinolysis. 2016;27:845–854.
   PubMed Web of Science ®Google Scholar
• Soucie JM, Cainfrini N, Janco RL, et al. Joint range of motion limitations among young males with haemophilia: prevalence and risk factors. Blood. 2004;103:2467–2473.
   PubMed Web of Science ®Google Scholar
• Klamroth R, Pollmann H, Hermans C, et al. The relative burden of hemophilia A and the impact of target joint development on health-related quality of life results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia. 2011;17:412–421.
   PubMed Web of Science ®Google Scholar
• Pollmann H, Richter H, Ringkamp H, et al. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr. 1999;158(Suppl.3):S166–170.
   PubMedGoogle Scholar
• Fischer K, Van der Born JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe haemophilia. Blood. 2002;99:2337–2341.
   PubMed Web of Science ®Google Scholar
• Pergantou H, Matsinos G, Papadopoulos A, et al. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilicarthropathy in children. Haemophilia. 2006;12:241–247.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med. 2007;357:535–544.
   PubMed Web of Science ®Google Scholar
• Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other muskulo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl. 1965;Suppl 77;1–132.
   Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment guidelines working group on behalf of the world federation of hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–e47.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939.
   PubMed Web of Science ®Google Scholar
• Rocino A, Coppola A, Franchini M, et al.; on behalf of the Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus. 2014;12:575–598.
   PubMed Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J ThrombHaemost. 2008;7:413–420.
   PubMed Web of Science ®Google Scholar
• Jimenez-Yuste V, Auerswald G, Benson G, et al. Achieving and maintaining an optimal through level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus. 2014;12(3):314–319.
   PubMed Web of Science ®Google Scholar
• Morfini M, Benson G, Jimenez-Yuste V, et al. Tailoring care to haemophilia patients’needs: which specialty and when? Blood Transfus. 2015;13:644–650.
   PubMed Web of Science ®Google Scholar
• Collins PW. Personalized prophylaxis in haemophilia patients. Haemophilia. 2012;18(Suppl 4):131–135.
   PubMed Web of Science ®Google Scholar
• Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014;20(Suppl 4):99–105.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia. 1997;3:1–8.
   PubMed Web of Science ®Google Scholar
• Shargel L, Yu A. Applied biopharmaceutics and pharmacokinetics. Stamford (CT): Appleton & Lange; 1999.
   Google Scholar
• Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia. 2005;11:571–582.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40:815–832.
   PubMed Web of Science ®Google Scholar
• Bjorkman S. Pharmacokinetics. In: Lee CA, Berntorp E, Hoots WK, editors. Textbook of hemophilia. 3rd ed. Oxford, Wiley Blackwell; 2014. p. 117–122.
   Google Scholar
• Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost. 1991;66:348–356.
   Google Scholar
• Berntorp E, Bjorkman S. The pharmacokinetics of clotting factor therapy. Haemophilia. 2003;9:353–359.
   PubMed Web of Science ®Google Scholar
• Lee CA. Pharmacokinetic studies in patients with inherited bleeding disorders-Challenges and relevance to clinical practice. Haemophilia. 2006;12:1–2.
   PubMed Web of Science ®Google Scholar
• Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337–342.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Van Mourik JA, Mertens K. The life cycle of coagulation FVIII in view of its structure and function. Blood. 1998;92:3983–3996.
   PubMed Web of Science ®Google Scholar
• Chavin SI. Factor VIII: structure and function in blood clotting. Am J Hematol. 1984;16:297–306.
   PubMed Web of Science ®Google Scholar
• Terraube V, O’Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010;16:3–13.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5:1353–1360.
   PubMed Web of Science ®Google Scholar
• Björkman S, Carlsson M, Berntorp E, et al. Pharmacokinetics of factor VIII in humans: obtaining clinically relevant data from comparative studies. Clin Pharmacokin. 1992;22:385–395.
   PubMed Web of Science ®Google Scholar
• Messori A, Longo G, Matucci M, et al. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokin. 1987;13:365–380.
   PubMed Web of Science ®Google Scholar
• Allain JP. Principles of in vivo recovery and survival studies. Scand J Haematol. 1984;33(Suppl. 41):123–130.
   PubMedGoogle Scholar
• Carlsson M, Berntorp E, Björkman S, et al. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol. 1993;51:247–252.
   PubMed Web of Science ®Google Scholar
• Collins PW, Fischer K, Morfini M, et al.; International Prophylaxis Study Group Pharmacokinetics Expert Working G. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17:2–10.
   PubMed Web of Science ®Google Scholar
• Björkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma-albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8:730–736.
   PubMed Web of Science ®Google Scholar
• Björkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationship of pharmacokinetics to age and body weight. Blood. 2012;119:612–618.
   PubMed Web of Science ®Google Scholar
• Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269–275.
   PubMed Web of Science ®Google Scholar
• Fijnvandraat K, Peters M, Ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol. 1995;91:474–476.
   PubMed Web of Science ®Google Scholar
• Van Dijk K, Van der Bom JG, Lenting PJ, et al. Factor VIII half-life and clinical phenotype of severe haemophilia A. Haematologica. 2005;90:494–498.
   PubMed Web of Science ®Google Scholar
• Allain JP, Frommel D. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in haemophilia A. Blood. 1976;47:973–982.
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Schulman S, Gitel S, et al. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol. 1992;82:729–734.
   PubMed Web of Science ®Google Scholar
• Schulman S, Varon D, Keller N, et al. Monoclonal purified FVIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost. 1994;72:403–407.
   PubMed Web of Science ®Google Scholar
• O’Donnel J, Laffan MA. The relationship between AB0 histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 2001;11:343–351.
   PubMed Web of Science ®Google Scholar
• Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost. 2000;83:65–69.
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Eng J Med. 1990;323:1800–1805.
   PubMed Web of Science ®Google Scholar
• Harrison JFM, Bloom AL, Abildgaard CF. The pharmacokinetics of recombinant factor VIII. Semin Hematol. 1991;28(Suppl.1):29–35.
   PubMedGoogle Scholar
• White GC, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (RecombinateTM) in previously treated patients with hemophilia A. Thromb Haemost. 1997;77:660–667.
   PubMed Web of Science ®Google Scholar
• Morfini M, Longo G, Messori A, et al. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). Thromb Haemost. 1992;68:433–435.
   PubMed Web of Science ®Google Scholar
• Fijnvandraat K, Berntorp E, Ten Cate JW, et al. Recombinant, B-domain deleted factor VIII (r-VIIISQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost. 1997;77:298–302.
   PubMed Web of Science ®Google Scholar
• Boedeker BG. Production processess of licensed recombinant factor VIII preparations. Semin Thromb Hemost. 2001;27:385–394.
   PubMed Web of Science ®Google Scholar
• Josephson CD, Abshire T. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement? Clin Adv Hematol Oncol. 2004 Jul;2(7):441–446.
   PubMedGoogle Scholar
• Sandberg H, Almstedt A, Brandt J, et al. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-FVIII SQ. Thromb Haemost. 2001;85:93–100.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Christophe OD, Gueguen P. The disappearing act of factor VIII. Haemophilia. 2010;16(102):6–15.
   PubMedGoogle Scholar
• Kosloski MP, Miclea RD, Balu-Iyer SV. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. Aaps J. 2009;11:424–431.
   PubMed Web of Science ®Google Scholar
• Leyte A, Van Schijndel HB, Niehrs C, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem. 1991;266:740–746.
   PubMed Web of Science ®Google Scholar
• Nielsen PF, Bak S, Vandhal B. Characterization of tyrosine sulphation in rFVIII (turoctog alfa) expressed in CHO and HEK-293 cells. Haemophilia. 2012 Sep;18(5):e937–e938.
   Web of Science ®Google Scholar
• Kannicht C, Ramstrom M, Kohla G, et al. Characterisation of the post-translational modifications of a novel, human cell line derived recombinant human factor VIII. Thromb Res. 2013;131:78–88.
   PubMed Web of Science ®Google Scholar
• Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16:349–359.
   PubMed Web of Science ®Google Scholar
• Sandberg H, Kannicht C, Stenlund P, et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res. 2012;130:808–817.
   PubMed Web of Science ®Google Scholar
• Klukowska A, Szczepanski T, Vdovin V, et al. Novel, human cell line-derived recombinant FVIII (Human-cl rhFVIII, Nuwiq) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. Haemophilia. 2015; Sept 14. DOI:10.1111/hae.12797.
   Google Scholar
• Ishaque A, Thrift J, Murphy JE, et al. Over-expression of Hsp70 in BHK-21 cells engineered to produce recombinant factor VIII promotes resistance to apoptosis and enhances secretion. Biotechnol Bioeng. 2007;97:144–155.
   PubMed Web of Science ®Google Scholar
• Garger S, Severs J, Regan L, et al. BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics. Haemophilia. 2017 Mar;23(2):e67–e78.
   PubMed Web of Science ®Google Scholar
• Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134:125–131.
   PubMed Web of Science ®Google Scholar
• Schmidbauer S, Witzel R, Robbel L, et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2015;136(2):388–395.
   PubMed Web of Science ®Google Scholar
• Shah A, Delesen H, Garger S, et al. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia. 2015;21:766–771.
   PubMed Web of Science ®Google Scholar
• Klamroth R, Simpson R, Von Depka-Prodzinski M, et al. Comparative pharmacokinetics of rVIII Single-Chain and octocogalfa (Advate®) in patients with severe hemophilia A. Haemophilia. 2016;22:730–738.
   PubMed Web of Science ®Google Scholar
• Laffan M. New products for treatment of haemophilia. Br J Haematol. 2016;172:23–31.
   PubMed Web of Science ®Google Scholar
• Berntorp E, Andersson NG. Prophylaxis for hemophilia in the era of extended half-life factor VIII/Factor IX products. Semin Thromb Hemost. 2016;42:518–525.
   PubMed Web of Science ®Google Scholar
• Mahalangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317–325.
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13:967–977.
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;27(126):1078–1085.
   Google Scholar
• Reding MT, Ng HJ, Poulsen LH, et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2016 Dec 19. DOI:10.1111/jth.13597.
   Google Scholar
• Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117:252–261.
   PubMed Web of Science ®Google Scholar
• Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII- Fc fusion protein. J Thromb Haemost. 2013;11:132–141.
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031–3037.
   PubMed Web of Science ®Google Scholar
• Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214–221.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Bossard MJ, Graninger M, et al. BAX855, a PEGylatedrFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie. 2012;32(Suppl1):S29–S38.
   PubMedGoogle Scholar
• Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013;121:2108–2116.
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-mantrial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11:670–678.
   PubMed Web of Science ®Google Scholar
• Coyle TE, Reding MT, Lin JC, et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended halflife, in subjects with hemophilia A. J Thromb Haemost. 2014;12:488–496.
   PubMed Web of Science ®Google Scholar
• Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16:747–766.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–2064.
   PubMed Web of Science ®Google Scholar
• Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol. 1991;32:669–670.
   PubMed Web of Science ®Google Scholar
• Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over age range 3-74 years. Eur J Clin Pharmacol. 2009;65:989–998.
   PubMed Web of Science ®Google Scholar
• Ruffo S, Messori A, Grasela TH, et al. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput Programs Biomed. 1985;19(2–3):167–177.
   PubMedGoogle Scholar
• Morfini M. The history of clotting factor concentrates pharmacokinetics. J Clin Med. 2017;6:35–49.
   Web of Science ®Google Scholar
• Iorio A, Keepanasseril A, Foster G, et al. Development of a web-accessible population pharmacokinetic service- hemophilia (WAPPS-Hemo) study protol. JMIR Res Protoc. 2016;5:e232.
   PubMed Web of Science ®Google Scholar
• Jimenez-Yuste V, Lejniece S, Klamroth R, et al. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight), in patients with hemophilia A. J Thromb Haemost. 2015;13:370–379.
   PubMed Web of Science ®Google Scholar